Leerink Swann maintains an 'Outperform' on Omnicare (OCR); Threat from CMS Proposal Appears Overstated
Tweet
Share
E-mailGet Alerts OCR Hot Sheet
Price: $97.90 --0%
Rating Summary:
2 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
2 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Leerink Swann maintains an 'Outperform' on Omnicare (NYSE: OCR) price target range $37-$40.
Leerink analyst says, "We highly doubt that CMS's recent proposal to require consultant pharmacists be independent of prescribing long-term care (LTC) pharmacy represents a major risk to OCR's business model. And to the degree that it potentially does represent a risk, we have little confidence in CMS's estimate of the expected cost savings, which appears to have been hastily constructed. With a double-digit EPS growth outlook, the potential catalyst of acquiring PMC, and a nearly 15% free cash flow yield, we view OCR as the most attractive stock in our coverage list."
For more ratings news on Omnicare click here and for the rating history of Omnicare click here.
Shares of Omnicare closed at $24.60 yesterday.
Leerink analyst says, "We highly doubt that CMS's recent proposal to require consultant pharmacists be independent of prescribing long-term care (LTC) pharmacy represents a major risk to OCR's business model. And to the degree that it potentially does represent a risk, we have little confidence in CMS's estimate of the expected cost savings, which appears to have been hastily constructed. With a double-digit EPS growth outlook, the potential catalyst of acquiring PMC, and a nearly 15% free cash flow yield, we view OCR as the most attractive stock in our coverage list."
For more ratings news on Omnicare click here and for the rating history of Omnicare click here.
Shares of Omnicare closed at $24.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
- Mizuho on Intel (INTC): "Just when you thought it could not get any worse..."
- Keurig Dr Pepper (KDP) PT Raised to $39 at Jefferies
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
